Correlation between Plasma Soluble CD36 Levels with Body Mass Index of Breast Cancer Patients in the Indonesian Population

Andhika Rachman, Cosphiadi Irawan, Aditia R.R., Sukamto Koesnoe, Indra Wijaya


The cluster of differentiation 36 (CD36) is a multiligand receptor protein that plays a role in lipid metabolism. Its biological functions involve lipid uptake, immune recognition, inflammation, molecular adhesion, and tumor metastasis. Soluble CD36 (sCD36) is the circulating form of CD36 in plasma. Research on the role of sCD36 in breast cancer is limited. This study aimed to investigate sCD36 concentration and evaluate the correlation between sCD36 concentration and BMI in breast cancer patients. This is a multi-center cross-sectional study done from June 2018 to February 2019 in Indonesia. Consecutive sampling was done for women with invasive breast cancer aged 18-70. Patients with locoregional recurrences, multiple comorbidities, diabetes, stroke, or liver impairment were excluded. Patients were grouped based on their BMI into normo-weight and overweight/obese. Plasma sCD36 was analyzed using Bioassay Laboratory™ ELISA. The correlation between plasma sCD36 and the patient's characteristics (metastasis status and molecular subtype) were then analyzed. A total of 76 patients were enrolled, 36 of whom were categorized into the overweight/obese group and 40 of them in the normo-weight. Plasma levels of sCD36 in breast cancer patients were higher than controls at 0.24±0.163 ng/mL and 0.46±0.175 ng/mL, respectively (p=0.006). However, no difference in plasma sCD36 levels was found between the overweight/obese group and the normo-weight breast cancer subjects (p>0.05). Plasma sCD36 increased significantly in breast cancer patients, but no significant difference was found based on body mass index. Further research is needed to determine the role of sCD36 in determining clinical outcomes and prognosis in breast cancer patients.

Keywords: Soluble CD36, body mass index, breast cancer, indonesia.

Full Text:



Balistreri, C.R., Caruso, C., and Candore, G., 2010, The role of adipose tissue and adipokines in obesity-related inflammatory diseases, Mediators Inflamm, 2010, 802078. CrossRef

Chmielewski, M., Bragfors-Helin, A.-C., Stenvinkel, P., Lindholm, B., and Anderstam, B., 2010, Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients, Clinica Chimica Acta, 411(23-24), 2079–2082. CrossRef

DeFilippis, R.A., Chang, H., Dumont, N., Rabban, J.T., Chen, Y.-Y., Fontenay, G.V., et al., 2012, CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues, Cancer Discov, 2(9), 826–839. CrossRef

Enciu, A.-M., Radu, E., Popescu, I.D., Hinescu, M.E., and Ceafalan, L.C., 2018a, Targeting CD36 as biomarker for metastasis prognostic: How far from translation into clinical practice?, Biomed Res Int 2018, 2018, 7801202. CrossRef

Enciu, A.-M., Radu, E., Popescu, I.D., Hinescu, M.E., and Ceafalan, L.C., 2018b, Targeting CD36 as biomarker for metastasis prognostic: How far from translation into clinical practice?, Biomed Res Int 2018, 2018, 7801202. CrossRef

Feng, W.W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., et al., 2019, CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies, Cell Rep, 29(11), 3405–3420. CrossRef

Fuster, J.J., Ouchi, N., Gokce, N., and Walsh, K., 2016, Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease, Circ Res, 118(11), 1786–1807. CrossRef

Globocan-IARC, 2018, Indonesian incidence, mortality, and prevalence by cancer site in 2018, Global Cancer Observatory: Cancer Today.

Handberg, A., Højlund, K., Gastaldelli, A., Flyvbjerg, A., Dekker, J.M., Petrie, J., et al., 2012, Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population, J Intern Med, 271(3), 294–304. CrossRef

Handberg, A., Levin, K., Højlund, K., and Beck-Nielsen, H., 2006, Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma, Circulation, 114(11), 1169–1176. CrossRef

Heebøll, S., Poulsen, M.K., Ornstrup, M.J., Kjær, T.N., Pedersen, S.B., Nielsen, S., et al., 2017, Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls, Int J Obes, 41, 262–267. CrossRef

Himoto, T., Tani, J., Miyoshi, H., Morishita, A., Yoneyama, H., Kurokohchi, K., et al., 2013, Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease, Diabetol Metab Syndr, 5, 51. CrossRef

Jiang, X., Zhao, X., Chen, R., Jiang, Q., and Zhou, B., 2017, Plasma soluble CD36, carotid intima-media thickness and cognitive function in patients with type 2 diabetes, Archives of Medical Science, 13(5), 1031–1039. CrossRef

Kaviani, A., Neishaboury, M., Mohammadzadeh, N., Ansari-damavandi, M., and Jamei, K., 2013, Effects of obesity on presentation of breast cancer, lymph node metastasis and patient survival: A retrospective review, Asian Pacific J Cancer Prev, 14(4), 2225–2229.

Kolb, R., Sutterwala, F.S., and Zhang, W., 2016, Obesity and cancer: inflammation bridges the two, Curr Opin Pharmacol, 29, 77–89. CrossRef

Krzystolik, A., Dziedziejko, V., Safranow, K., Kurzawski, G., Rać, M., Sagasz-Tysiewicz, D., et al., 2015, Is plasma soluble CD36 associated with cardiovascular risk factors in early onset coronary artery disease patients?, Scand J Clin Lab Invest, 75(5), 398–406. CrossRef

Liang, Y., Han, H., Liu, L., Duan, Y., Yang, X., Ma, C., et al., 2018, CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells, Oncogenesis, 7, 98. CrossRef

Love-Gregory, L., and Abumrad, N.A., 2011, CD36 genetics and the metabolic complications of obesity, Curr Opin Clin Nutr Metab Care, 14(6), 527–534. CrossRef

Nattenmüller, C.J., Kriegsmann, M., Sookthai, D., Fortner, R.T., Steffen, A., Walter, B., et al., 2018, Obesity as risk factor for subtypes of breast cancer: Results from a prospective cohort study, BMC Cancer, 18, 616. CrossRef

Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C.S.-O., et al., 2017, Targeting metastasis-initiating cells through the fatty acid receptor CD36, Nature, 541, 41–45. CrossRef

Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al., 2000a, Molecular portraits of human breast tumours, Nature, 406, 747–752. CrossRef

Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al., 2000b, Molecular portraits of human breast tumours, Nature, 406, 747–752. CrossRef

Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J.J., Friedman, E.R., and Slingerland, J.M., 2017, Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention, CA Cancer J Clin, 67(5), 378–397. CrossRef

Radvanyi, L., Singh-Sandhu, D., Gallichan, S., Lovitt, C., Pedyczak, A., Mallo, G., et al., 2005, The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer, Proceedings, National Academy of Sciences, 102(31), 11005–11010. CrossRef

Richardson, A.L., Wang, Z.C., De Nicolo, A., Lu, X., Brown, M., Miron, A., et al., 2006, X chromosomal abnormalities in basal-like human breast cancer, Cancer Cell, 9(2), 121–132. CrossRef

Shiju, T.M., Mohan, V., Balasubramanyam, M., and Viswanathan, P., 2015, Soluble CD36 in plasma and urine: A plausible prognostic marker for diabetic nephropathy, J Diabetes Complications, 29(3), 400–406. CrossRef

Silverstein, R.L., and Febbraio, M., 2009, CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior, Sci Signal, 2(72). CrossRef

Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al., 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings, National Academy of Sciences, 98(19), 10869–10874. CrossRef

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F., 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71(3), 209-249. CrossRef

Uray, I.P., Liang, Y., and Hyder, S.M., 2004, Estradiol down-regulates CD36 expression in human breast cancer cells, Cancer Lett, 207(1), 101–107. CrossRef

Wang, J., and Li, Y., 2019, CD36 tango in cancer: Signaling pathways and functions, Theranostics, 9(17), 4893–4908. CrossRef

WHO, 2022, WHO Fact Sheet, International Agency for Research on Cancer.

Woo, M.-S., Yang, J., Beltran, C., and Cho, S., 2016, Cell Surface CD36 Protein in monocyte/macrophage contributes to phagocytosis during the resolution phase of ischemic stroke in mice, Journal of Biological Chemistry, 291(45), 23654–23661. CrossRef

Xu, W.H., Qu, Y.Y., Wang, J., Wang, H.K., Wan, F.N., Zhang, H.L., et al., 2019, Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients, J Cancer, 10(19), 4522–4531. CrossRef

Yu, X., Guo, C., Fisher, P.B., Subjeck, J.R., and Wang, X.-Y., 2015, Scavenger receptors: emerging roles in cancer biology and immunology, Advances in Cancer Research, 128, 309–364. CrossRef

Zhao, H., Langerød, A., Ji, Y., Nowels, K.W., Nesland, J.M., Tibshirani, R., et al., 2004, Different gene expression patterns in invasive lobular and ductal carcinomas of the breast, Mol Biol Cell, 15(6), 2523–2536. CrossRef

Zhao, J., Zhi, Z., Wang, C., Xing, H., Song, G., Yu, X., et al., 2017, Exogenous lipids promote the growth of breast cancer cells via CD36, Oncol Rep, 38(4), 2105–2115. CrossRef


Copyright (c) 2023 Andhika Rachman

Indexed by:




Indonesian Society for Cancer Chemoprevention